Company intelligence / Profile preview
Enalare Therapeutics
Princeton, New Jersey, United Statesenalare.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Enalare is developing ENA-001, an agnostic respiratory stimulant with a novel mechanism of action. The company has completed multiple preclinical studies and is advancing clinical trials for various indications including drug overdose respiratory depression and post-operative respiratory depression. The FDA has recently cleared the company to initiate a Phase 1 clinical study of ENA-001 for respiratory depression associated with drug overdose.
- Therapeutic areas
- OtherPulmonologyPsychiatryInfectious Diseases
- Modalities
- Small moleculesNew Chemical Entities (NCEs)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Biomedical Advanced Research and Development Authority (BARDA)Eagle Pharmaceuticals
Beyond the preview
Go deeper on Enalare Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enalare Therapeutics.